AdipoPharma is a French biotech company focused on leveraging the unique properties of adipocyte cells to address insulin resistance, type 2 diabetes, and related metabolic disorders. The company’s research, spearheaded by founder Dr. Vincent Marion, has centered on understanding the adipocyte's role in lipid biosynthesis and whole-body lipid homeostasis. Through extensive genetic studies, particularly on Alström syndrome, AdipoPharma has identified therapeutic targets that highlight the adipocyte's influence on metabolic health. This foundational research has culminated in the development of a proprietary therapeutic peptide known as "PATAS," which is poised to enter clinical trials in 2025.

PATAS represents a novel approach to treating diabetes by restoring healthy lipid biosynthesis in dysfunctional adipocytes, thereby reducing harmful lipids such as ceramides. This innovative peptide is anticipated to be the first anti-diabetic drug to significantly improve insulin resistance and address complications like beta cell plaque accumulation, liver steatosis, and fibrosis. By targeting the underlying lipid management issues associated with diabetes, AdipoPharma aims to provide a safe and effective treatment option that could also mitigate cardiovascular dysfunction linked to the disease.

France

AdipoPharma SAS is a French biotech company with a US subsidiary committed to understanding the role of the adipocyte cells in diabetes via their unique effect on lipid biosynthesis and management of whole-body lipid homeostasis.

Our first-in-class candidate - PATAS - is set to enter clinical trials later this year.

AdipoPharma SAS

Company Details